Despite advances in our knowledge about the genesis, molecular biology, and natural history of malignant gliomas and the use of a multi-disciplinary approach to their treatment, patients harboring this diagnosis continue to face a grim prognosis. At the time of diagnosis, patients typically undergo surgery for the establishment of a histologic diagnosis, the reduction of tumor burden, and the relief of mass effect, with the maintenance of the patient's neurological function in mind. This is followed by the administration of adjuvant therapeutics, including radiation therapy and chemotherapy.
Introduction
While primary brain tumors account for only 2% of all adult cancers, malignant gliomas [including anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM)] portend a grim prognosis and result in a disproportionate rate of disability and mortality. The treatment of patients with primary brain tumors remains a major challenge. The standard of care for patients with newly diagnosed GBM consists of concurrent radiation therapy and temozolomide, followed by six months adjuvant or maintenance temozolomide. This schema is based on the work of Stupp et al. (1) , which reported a median survival of 14.6 months and two-year overall survival of 27% in patients treated in this manner. The addition of temozolomide did not negatively affect the patients' health-related quality of life (2). Despite aggressive treatment using conventional therapy (sur-Technology in Cancer Research & Treatment, Volume 5, Number 3, June 2006 gery, radiation therapy, and chemotherapy), the median life expectancy for a patient diagnosed with GBM is only 12-14 months with a two and five-year survival of only 8-12% and <1% (3). Failure to substantially improve survival is due to the limited activity of many agents, the inherent or acquired resistance of these tumors, and the obstacles of delivery of anti-cancer agents to the brain. In this review, we will focus on the nature of some of these obstacles and discuss modalities that are being used to circumvent them, focusing on local and convection-enhanced delivery (CED).
Physiologic "Barriers"
The Blood-Brain Barrier (BBB) Unlike peripheral capillaries that allow relatively free exchange of substances across and between cells, the periendothelial structures of the BBB pose a physical and metabolic limit to the transportation of substances from the peripheral circulation into the brain. The mean intercapillary distance in the human brain is approximately 40 μm (4). This short distance allows for near instantaneous solute equilibration throughout the brain interstitial space for small molecules, once the BBB has been overcome. However, the nature of the BBB is such that it blocks the passage of molecules except those that cross cell membranes by means of lipid solubility (e.g., gases, ethanol, lipophilic drugs) and those which are allowed in by specific transport systems (such as sugars and some amino acids). Transit across the BBB involves translocation through: i) the capillary endothelium, ii) the internal cytoplasmic domain, and iii) through the ablumenal membrane and pericyte or basal lamina. It is generally accepted that substances with a molecular weight higher than 500 Daltons (Da) cannot cross the BBB. This limitation may exclude the use of otherwise highly bioactive chemotherapeutic agents currently in development; in other words, antitumor agents must be small in size and lipophilic in nature in order to reach their target following enteral or parenteral administration. This limitation is most apparent when considering monoclonal antibodies. The one caveat is that enhancing tumors have a dysfunctional BBB.
In addition to the physical barrier imposed by the BBB, there is also an enzymatic barrier at the cerebral endothelia, capable of metabolizing drugs and nutrients (5-7). These enzymes are principally directed at metabolizing neuroactive blood-borne solutes. Enzymes such as g -glutamyl transpeptidase (g -GTP), alkaline phosphatase, and aromatic acid decarboxylase are in elevated concentration in cerebral microvessels, yet often in low concentration or absent in non-neuronal capillaries.
A number of carrier transport systems at the BBB are responsible for brain uptake of nutrients and their analogs from the systemic circulation. Transport systems exist for glucose (8), amino acids (9,10), choline (11), vitamins (12, 13) , low density lipoprotein (14) , and nucleosides (13). Multiple groups have attempted to employ these active transport mechanisms for drug delivery by designing chemotherapeutic agents that possess a moiety mimicking the natural substrate of the carrier transporters (15). These efforts have not proven effective.
The ability of a particular substance to cross the BBB and enter the brain is dependent upon several factors: The concentration between compartments, size of the molecule (i.e., molecular weight), flexibility and conformation of the molecule, amino acid composition, lipophilicity, cellular enzymatic stability, cellular sequestration, affinity for efflux mechanisms (i.e., P-glycoprotein), hydrogen bonding potential (i.e., charge), affinity for carrier mechanisms, and effects of existing pathological conditions.
The Blood-Tumor Barrier (BTB)
Multiple authors have argued that the limitations posed by the BBB are secondary to the success of brain tumor chemotherapy; rather, of more importance is the BTB. In brain tumors, permeability of substances from tumor vasculature into tumor substance is a complex process governed by two major variables, the nature of the tumor microvasculature and the spatial distribution of these target capillaries. The capillary structure of high-grade gliomas differs significantly from that of the normal brain. Three distinct microvessel populations in brain tumors have been described (16): i) continuous, nonfenestrated capillaries like those of normal brain; ii) continuous, fenestrated capillaries; tumors with these microvessels exhibit increased permeability to small but not to large molecules; and iii) interendothelial gaps that may measure as large as 1 μm. The latter vessels do not display selectivity for large molecules.
Despite the presence of these gaps in the capillary endothelial barrier, the spatial arrangement of microvasculature within the tumor parenchyma limits the effective translocation of drugs across the BTB into tumor. While the mean intercapillary distance in the human brain is quite constant, the respective intercapillary distance in tumor is highly variable. Once a substance has crossed the BTB, its further movement is constrained by the limitation of passive diffusion (discussed in a following section). Burger (17) has demonstrated that tumor cells may reside centimeters away from the tumor margin, thus the infiltrative nature of high grade gliomas limits the practical differences between the permeability of the BBB and BTB. the choroid plexus. Delivery of therapeutic agents utilizing the choroid plexus to access the ventriculocisternal circulation, and thus into the brain parenchyma is limited by the BCB, whose presence was first demonstrated by Goldmann in 1913. Unlike the BBB, the BCB has been demonstrated to be selectively permeable (18) . While the capillaries of the choroid plexus are fenestrated, non-continuous, and have gaps between the capillary endothelial cells allowing the freemovement of small molecules, the adjacent choroidal epithelial cells form tight junctions, preventing most macromolecules from effectively passing into the CSF from the blood (19). However, these epithelial-like cells have shown to have a low resistance as compared the cerebral endothelial cells, approximately 200 Ω·cm 2 between blood and CSF, suggesting that the BCB is much more permeable than the BBB (20).
Despite the greater permeability of the BCB compared to the BBB, the efficacy of drug delivery by ventriculocisternal perfusion remains limited. Blasberg et al. (21) injected low-molecular weight (76 to 454 Da) radiolabeled drug into the lateral ventricle in rhesus monkeys. Following injection, they found minimal evidence of drug in the systemic circulation. However, they also noted minimal diffusion of drug into the brain parenchyma, reporting a 2.5-to 10-fold reduction in drug concentration 1 mm from the ventricular surface. While small to mid-size molecules were able to translocate across the blood-CSF barrier, their egress into brain parenchyma remained confined by the limits of passive diffusion (discussed in the following section). In addition, the continuous flow of CSF through the ventricular system and over the convexity of the brain provides a "sink" that reduces the steady-state concentration of a molecule penetrating into the brain and CSF (22). This "sink" effect is greater the slower a molecule moves, which makes it particularly important for lipid-insoluble molecules of large molecular radius (23).
Physiologic Transport Phenomena

Diffusion
Diffusion is a passive transport phenomena dependent upon the free concentration gradient and diffusion coefficient of a given compound in a given tissue. Passive diffusion through the brain is dependent on the physical properties of the interstitum and on the molecular weight of the substance being delivered. Diffusion of higher molecular weight substances at a particular free concentration gradient is substantially less than diffusion of a small molecular weight compound at the same free concentration gradient. After delivery of drug into the brain interstitium, limited distribution of drug by diffusion constrains the therapeutic treatment volume.
Multiple local drug delivery strategies have been utilized to maximize drug delivery by diffusion into the brain pa-renchyma. The prototype agent delivered to the tumor bed after surgical resection is Gliadel™, a biodegradable polymer wafer impregnated with carmustine (BCNU). In a mutli-center trial of patients with recurrent GBM, Brem et al. found that implantation of Gliadel™ wafers at the time of reoperation was associated with a median survival time of 31 weeks, compared to a median survival time of 23 weeks in patient who received placebo wafers (24). A recent update on long term follow up of 207 patients randomized to Gliadel™ or placebo in newly diagnosed patients found that the median survival was 13.8 months compared to 11.6 months, respectively (25, 26) .
Unfortunately, the diffusion of high molecular weight compounds in brain and tumor is very slow (27) (28) (29) . Lower molecular weight compounds have a higher diffusivity in brain and tumor, but their efficacy beyond a few millimeters is limited by capillary uptake and metabolism (30-32). The physical limitations of diffusion in the brain require that very high doses of drug be delivered to ensure passage of even minimal concentrations of drug beyond the immediate delivery site. This constraint arises whether one considers drug delivery via the systemic circulation, ventriculocisternal perfusion, or local delivery. It was the realization of the limits of passive diffusion that led to interest in bulk-flow-dependent strategies for drug delivery to the brain.
Other Agents in Development Using Diffusion:
DTI-015: DTI-015 is a new formulation of carmustine (BCNU) that has recently received orphan drug designation by the FDA. Specifically, DTI-015 uses absolute ethanol, a water-miscible organic solvent, to dissolve carmustine. This formulation is utilized in a new technique of drug delivery coined solvent facilitated perfusion (SFP), in which the solvent, by virtue of its pharmacologic properties, allows the delivery of the chemotherapeutic agent through both aqueous solutions and cellular membranes, increasing the depth of penetration of the agent through the target tumor. The advent of this formulation arose in part from the limited diffusion of BCNU (33) and the modest clinical benefit of Gliadel™ (24, 25) . This new formulation has, however, demonstrated excellent preclinical efficacy in rats bearing intracranial 9L and T9 gliosarcoma (34); a single injection of DTI-015 resulted in a 40% cure rate and over a 400% increase in average survival (35).
Results of a Phase I/II trial was recently reported in which 40 heavily treated patients with inoperable recurrent malignant gliomas received IT DTI-015 under stereotactic MRI guidance (36). A MTD of 5ml and 240mg was established in this trial; 89% of patients receiving DTI-015 at or below the MTD tolerated the treatment without significant drug-related adverse events. The median survival among patients with recurrent GBM was 55 weeks. Chlorotoxin (I 131 -TM-601): Chlorotoxin is a 36-amino acid peptide derived from the scorpion (Leiurus Quinquestriatus) venom; it binds to a chloride channel expressed on gliomas (37). This peptide specifically binds to malignant brain tumors but not to normal brain tissues (38), resulting in inhibited glioma cell migration (39). Chlorotoxin conjugated to I 131 has been the focus of investigation as a novel therapy.
The preclinical data were presented in 2003 at the Advance in the Application of Monoclonal Antibodies in Clinical Oncology Conference in Latchi, Cyprus (39). The investigators reported that a single dose of 131 I-TM-601 administered by direct injection into nude mice bearing human xenograft extended survival up to 269%. Furthermore, I 131 -TM-601 was found to be without significant toxicity when administered to rodents and primates.
In a Phase I/II trial, 18 patients (17 GBM), were injected with I 131 -TM-601 directly into the tumor resection cavity within 14 to 28 days after surgery. The agent was well tolerated and SPECT data demonstrated the presence of the agent in the vicinity of the tumor up to 168 hours after injection (40). Median survival was 25.2 weeks. A Phase II study is underway with a goal accrual of 66 patients with confirmed diagnosis of recurrent glioma. I 131 -TM-601 has received orphan drug designation and fast track development by the FDA. 131 I-labeled Antitenascin Monoclonal Antibody 81C6: Tenascin is an extracellular matrix hexabrachion glycoprotein expressed in high-grade gliomas but not in normal brain (41). 81C6 is a murine monoclonal antibody that binds a specific epitope of tenascin and reacts with tenascin-expressing tumors (41). In vivo, 131 I-81C6 use has led to delayed tumor growth and apparent tumor cures in both flank (42) and intracranial (43) models.
Phase I/II studies have been conducted using I 131 -81C6 among patients with recurrent high grade gliomas and newly diagnosed gliomas. In 34 patients with previously irradiated recurrent primary or metastatic brain tumors, I 131 -81C6 was administered by direct injection through a reservoir left in a surgically created resection cavity. The MTD was 100 mCi and the dose-limiting toxicity was both hematologic (neutropenia and thrombocytopenia) and neurologic (seizures, hemiparesis, aphasia, and headaches), seen at 120mCi. The median survival from the time of treatment among GBM patients (N=26) was 56 weeks and 60 weeks for all patients (44). In a subsequent Phase II trial, 100 mCI of I 131 -81C6 was injected into the surgically created resection cavity in 43 patients with recurrent primary or metastatic malignant brain tumors. Median overall survival from the time of treatment among patients with GBM/gliosarcoma was 64 weeks and 99 weeks for those with AA/anaplastic oligodendroglioma (45). Further trials are planned in this group of patients.
In a phase I trial investigating I 131 -81C6 toxicity among patients with newly diagnosed GBM, 42 patients underwent dose escalation; the MTD was 120 mCi. The median survival for patients with GBM was 69 weeks, and for all patients, 79 weeks (46). In a follow-up Phase II trial in this cohort of newly diagnosed GBM, 120mCi of 131 I-81C6 was delivered by direct injection into the surgically created resection cavity. Median overall survival of patients with GBM (N=27) was 79.4 weeks and 86.7 weeks for all patients (47). A phase III trial is planned for this cohort.
Convection-Enhanced Delivery
Fluid convection is a transport phenomena that occurs as a result of a pressure gradient (bulk flow). Bulk flow of brain interstitial fluid occurs under normal physiologic conditions, as may be demonstrated by injection of a marker into the brain parenchyma (48). It also accounts for the mechanics of vasogenic edema, and for the movement of solutions after direct injection into the brain parenchyma (49). Substrate distribution by bulk flow is a function of the hydrostatic pressure at which the substrate is delivered, independent of concentration or molecular weight. Within a homogeneous isotropic medium, bulk flow will result in a spherical distribution of substrate away from the infusion site (49). This process allows for very homogeneous delivery of small or large molecules into the brain parenchyma; micro-infusion of transferrin under conditions maximizing bulk flow demonstrated a concentration reduction of only 0.015% at the leading edge of the infusion profile at 1.5 cm from the infusion site (50).
Convection-enhanced delivery (CED) is a catheter-based, microinfusion drug delivery mechanism that utilizes the properties of bulk flow. Animal studies and preclinical data suggested that CED is a promising strategy for drug delivery into the CNS (51, 52). Infusion catheters are placed using stereotactic guidance, allowing delivery of drug via a steadystate infusion system. A rate of infusion is chosen that exceeds the rate at which the brain can remove fluid from the interstitial space (0.3-0.5 μL/min/mL) but is less than the rate at which leakage from the infusion cannula tract may occur. Using flow rates from 0.5 to 6.0 μL/min in animal models, the apparent volume of distribution exceeded the volume of infusion by 5-to 10-fold (53, 54). Preclinical and Phase I studies have shown CED to be a safe system for drug delivery to the brain (55-57). Adverse effects were primarily limited to the CNS and appeared to be related to increased cerebral edema following drug administration. In almost all cases, neurologic deficits were transient, likely due to the "fluid" infused and less so drug toxicity, and responded to medical therapy for cerebral edema or improvement of seizure therapy. In the following sections, trials underway for GBM therapy using CED are discussed.
IL-13/Pseudomonas Exotoxin Fusion Protein (IL13-PE38QQR):
IL13-PE38QQR has orphan drug designation in the United States and is on a fast-track drug development status from the FDA. It is the most clinically advanced of the targeted cytotoxins; the Phase III PRECISE trial recently closed to patient recruitment but on going follow-up continues. The scientific basis behind the development of IL13-PE38QQR stems from the identification of an interleukin-13 receptor (IL-13R), an immune cytokine, as a potentially unique marker specific for high grade gliomas. Specifically, the IL-13Rα2 subtype is highly expressed in a number of human malignant glioma cell lines (58) and 72% of tumor explants, while normal human immune cells and brain tissue show low to no levels of IL-13R (59). Therefore, IL-13R was felt to serve as a glioma-specific receptor for directing targeted therapeutics.
IL13-PE38QQR is a chimeric fusion protein made of IL-13, which serves as the receptor-specific ligand to IL-13R, and a modified form of the Pseudomonas aeruginosa exotoxin, a known cytotoxic protein that induces cell death by the arrest of cellular protein synthesis via ADP-ribosylation of elongation factor 2 (EF-2) (60, 61). In vitro, IL13-PE38QQR was found to be selectively cytotoxic to glioma cells but not to normal astrocytes, endothelial cells, or immune cells; furthermore, the cytotoxic effect was shown to correlate with the number of IL-13R present on the cell surface. Among glioma cell lines with higher receptor expression, low concentrations of IL13-PE38QQR were needed, often in the picomolar (pM) range, for cytotoxic effect (58). This cytotoxic mechanism also proved to be IL-13R specific by competitive inhibition of IL-13PE38QQR using excess IL-13, the native ligand for IL-13R, in the experimental design.
In animal studies, nude mice bearing human glioma cell line xenografts in their flank were treated with IL13-PE38QQR administered by several different routes, including intravenous (IV), intraperitoneal (IP), and direct intratumoral (IT) (62). Several different doses and dosing schedules were tested but the most superior results were seen with daily or alternate day IT injections of 50 or 100μg/kg/day doses for five doses; this resulted in complete and durable regression (at least 221 days) of the xenograft tumors in 80% and 100% of the animals, respectively (62). To investigate toxicity to normal brain, IL13-PE38QQR was infused into the right frontal lobe of rats. Four days after infusion, normal rat behavior was noted and histological analysis of the brains demonstrated little necrosis at the 100μg/ml dose but liquefactive necrosis, degenerating neurons, and cerebral edema at the 500μg/ml dose (52).
Based on encouraging preclinical data, clinical trials were initiated in 2000. There were several Phase I/II trials with IL13-PE38QQR in patients with recurrent malignant gliomas, each addressing different questions. The first trial used CED delivering IL13-PE38QQR IT at 200μl/catheter/hr for 96 hours, a dose escalation scheme, which started at 0.125μg/ml, was designed to detect the maximum tolerated dose (MTD). A second infusion was given eight weeks later (52, 63, 64) .
The second Phase I/II trial was designed to determine the histologically-effective concentration of IL13-PE38QQR after IT infusion as evidenced by tumor cytotoxicity of > 90% cell necrosis in the post-infusion specimen when compared to the pre-infusion biopsy specimen; this effect was hypothesized to be lower than the MTD. IL13-PE38QQR was infused IT and then the tumor was resected four days after completion of the infusion. This resection was then followed by a 96 hour peritumoral (PT) infusion of IL13-PE38QQR starting two days after surgical resection; dose escalation was carried out for the second infusion to determine the MTD of IL13-PE38QQR in brain with tumor infiltration (52, 63, 64).
The final Phase I/II trial was designed to determine the maximally tolerated combination of IL13-PE38QQR concentration and duration of infusion, when delivered by CED through one or two IT catheters prior to surgical resection. The duration of infusion was varied from four to seven days (96 to 168 hours); when the maximally tolerated duration was determined, the concentration of IL13-PEQQR was incrementally increased, starting at 0.5μg/ml (52, 63, 64) .
Results of these three Phase I/II trials were presented at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting (64). In aggregate, 74 patients were enrolled in the three Phase I/II trials. The MTD for PT infusion was reported as 0.5μg/ml, where non-specific necrosis of tumor-infiltrated and normal brain occurred at 1μg/ml; up to 3μg/ml concentrations were tolerated. Overall better survival was seen among patients with WHO Grade IV astrocytomas receiving PT infusions compared to patients given IT infusions; and within the group of patients receiving PT infusions, those who had more than two "optimally" placed catheters had a mean survival of 70.3 weeks compared to 41.4 weeks for those who did not.
Based on these Phase I/II trial results demonstrating a median survival among patients with GBM of 39.0 weeks, the Phase III PRECISE trial was initiated in February 2004, comparing IL13-PE38QQR to Gliadel™ wafers, randomizing 300 patients in a 2:1 ratio to IL13-PE38QQR or Gliadel™, respectively. The goal of the trial was to demonstrate a 50% increase in survival 42 weeks (compared to 28 weeks) in the cohort of patients treated by IL13-PE38QQR compared to Gliadel™. The trial is closed to accrual and results are eagerly awaited. -4(38-37) receptor, IL-4 receptor (IL-4R) was found to be overexpressed in human malignant glioma cell lines (65). The overexpression of IL-4R was confirmed by immunohistochemical staining among surgical samples of WHO Grade III and IV astrocytomas at a rate of 83 and 86%, respectively (66). In contrast, normal brain samples expressed little or no levels of IL-4R, as detected by reverse transcriptase polymerase chain reaction (RT-PCR) (67). IL-4R was also identified as a potential candidate for the delivery of targeted therapeutic agents.
IL4/Pseudomonas Exotoxin (IL
The natural ligand to the IL-4R, Interleukin-4 (IL-4), is another platform upon which a fusion protein with Pseudomonas aeruginosa exotoxin cold be constructed (65). The fusion protein, IL-4-PE38, is conceptually similar to the IL13-PE38QQR protein, in which IL-4 is the ligand supplying the target specificity and entry mechanism for the exotoxin. Over the course of preclinical development, however, the protein was further modified to make its affinity for the IL-4R greater than the receptor's natural ligand and renamed IL-4(38-37)-PE38KDEL (68). Compared to the unmodified protein, IL-4(38-37)-PE38KDEL was also found to be three to 30-fold more cytotoxic to GBM cell lines compared to the unmodified protein; GBM cells were also 25 to 74 times more sensitive compared to normal astrocytes or a neuronal cell line (67).
In vivo, IL-4(38-37)-PE38KDEL demonstrated antitumor activity in a dose-response fashion when delivered by IV, IP, and IT routes to nude mice bearing subcutaneous human glioma xenografts (69). When administered IT at a dose of 250μg/kg (three doses on alternate days), significant reduction in tumor size was seen by Day 10 and complete tumor regression was seen by Day 24 in all treated mice. Despite these encouraging results, 50% of the mice experienced a recurrence by Day 37, although the sizes of the tumors were significantly smaller than the control group. This in vivo experiment was then repeated with a higher dose of 750μg/kg (three doses on alternate days) and complete tumor regression was seen in all the mice. Furthermore, this result was durable for over 100 days (69). On the basis of this encouraging result, human trials were begun.
In 2000, the results of the initial Phase I study were reported (70). The safety and tolerability of IL-4(38-37)-PE-38KDEL was tested in nine patients with recurrent highgrade gliomas. Starting at a concentration of 0.2μg/ml, IL-4(38-37)-PE38KDEL was infused by CED through one to three catheters at 0.3-0.6 ml/hr for a duration of four to eight days; dose escalation occurred to a maximum concentration of 6μg/ml in this trial, although the MTD was not determined. No symptoms of increased intracranial pressure (ICP) was seen during the infusion; no systemic toxicity occurred; and six of the nine patients showed necrosis on imaging studies, of which one patient remained disease-free for more than 18 months (70). This trial was followed by another Phase I/II dose escalation study in which IL-4(38-37)-PE38KDEL was delivered IT by CED in patients with recurrent malignant glioma (54). Thirty-one patients were enrolled, 25 with GBM and six with AA were assigned to one of four dosing groups with concentration of the cytotoxin at 6, 9, and 15μg/ml in 40 or 100ml volumes to attain a total dose delivery of 240, 360, 600, or 900μg. The infusions were again well tolerated, with no deaths or drug-related systemic toxicity. Grade 3 or 4 toxicity, such as perforated duodenal ulcer, hemiparesis, fatigue, aphasia, seizures, and cerebral edema, was seen in 39% of patients in all dose groups and in 22% of the patients at the MTD of 6μg/ml (240μg total dose delivered). MRIs with gadolinium infusion, demonstrated areas of decreased signal intensity, consistent with necrosis, within the treated tumors in many patients. The median overall survival was 8.2 months for all patients and 5.8 months for those with a GBM; the six and 12 month survival was 52% and 48%.
TGFα/Pseudomonas Exotoxin Fusion Protein (TP-38):
Malignant gliomas overexpress the epidermal growth factor receptor (EGFR), often due to amplification of the EGFR gene (71). In contrast, EGFR is expressed at very low levels or is undetectable on normal human glial and neuronal cells. There are two natural ligands for EGFR: transforming growth factor alpha (TGF-α) and epidermal growth factor (EGF).
Using the overexpressed EGFR as the selective target, a fusion protein of TGF-α and the Pseudomonas aeruginosa exotoxin, PE-38, was made. This fusion protein, TP-38, showed very potent cytotoxic effects on seven of eight tested glioma cell lines at concentrations as low as 0.5ng/ml(72). Early in vivo testing was done, using a continuous intraperitoneal infusion via an implanted pump, against a nude mice flank xenograft model. A reduction in tumor size and growth was observed beyond the seven-day infusion period but no complete response was seen.
The in vivo experiment which led to the first phase I/II trial was conducted in an athymic murine intracranial xenograft tumor model. TP-38 was delivered intracranially at a total dose of 0.03μg or 0.1μg in a volume of 20μl, and there was a significant improvement in survival, with 100% and 90%, respectively, of the mice surviving without evidence of tumor compared to control animals that died, on average, by Day 19 of the experiment. Higher doses of TP-38 did not increase survival or durable tumor control; in fact, due to toxicity of TP-38, an increased animal death was observed (57). The robust and dramatic response to TP-38 led to Phase I clinical trials.
In a dose-escalation study to define the MTD, dose-limiting toxicity, and early efficacy among patients with recurrent malignant brain tumors of less than 5cm in diameter, twenty patients were enrolled. Through two catheters, TP-38 was in-fused by CED at 0.4ml/hr for 50 hours (total volume of 40ml; total dose of 1μg). The total delivered dose was escalated to 2μg and 4μg, achieved by varying the drug concentration while maintaining a constant infused volume. TP-38 was well tolerated by all the patients in this trial but an MTD was not determined. One patient experienced a Grade 4 fatigue at the highest tested concentration. Early efficacy data indicate that among 15 patients who had evidence of residual tumor at the time of treatment, three demonstrated radiographic responses, of which one patient had a complete response and has survived longer than 83 weeks at the time of publication; the median survival for all patients was 23 weeks but 31.9 weeks if there was no residual tumor prior to treatment (57).
Transferrin/Diphtheria Toxin (Tf-CRM107):
Tf-CRM107 is another fusion protein that has received orphan drug designation and is on the fast-track drug development status by the FDA. The selective property of this protein construct was achieved by targeting the transferrin receptor (TfR), which is upregulated and overexpressed among cells that are metabolically active. It has been found that the TfR is readily detected on rapidly dividing cells, including gliomas (73), but not normal brain (although it is found along the luminal surface of capillaries) (74). Expression of TfR increases with the increasing glioma grade (73).
Diphtheria toxin incites cell death through the same cellular protein target as the Pseudomonas aeruginosa exotoxin: elongation factor-2 (EF-2). By interfering with down-stream protein synthesis, cell death ensues. In synthesizing the fusion protein between transferrin and the Diphtheria toxin, a point mutation in the toxin was made (CRM107), which inactivated the non-specific binding of this toxin to mammalian cells, while retaining its enzymatic function, EF-2 inactivation, intact (75). Preclinical testing was begun with the resulting fusion protein, Tf-CRM107.
In in vitro experiments, free Diphtheria toxin, CRM107, was found to be 1,000 to 100,000-fold less toxic than Tf-CRM107 against three glioblastoma cell lines due to the lack of cell-specific binding; the potent activity of Tf-CRM107 was shown to be TfR-specific by the reduction in cytotoxic activity by the addition of unconjugated transferrin to the assay (76). Tf-CRM107 was, therefore, felt to possess high specificity and cytotoxicity at low concentrations, warranting further preclinical investigation.
In nude mice bearing flank tumor xenograft, Tf-CRM107 was compared to CRM107 and phosphate-buffered saline (PBS) in its ability to inhibit tumor growth when delivered IT for four doses on alternate days. By Day 14, greater than 95% regression of the tumor mass was seen, and no tumor recurrence occurred by Day 30, whereas unconjugated CRM107 was 10-100 times less effective (77). In addition, a dose-response relationship was demonstrated in escalating doses of 0.1, 1, or 10 μg, with some animals having complete responses.
In a Phase I/II trial to determine the MTD and early antitumor efficacy (55), 15 patients with recurrent or progressive malignant gliomas (nine GBM, five AA, one anaplastic oligodendroglioma) were treated with intratumoral Tf-CRM107 delivered through one to three catheters by CED in increasing doses. The initial concentration delivered was 0.1μg/ml and the volume 5ml, although the volume was later increased as high as 180ml. Nine patients had reduction in tumor volume by 50% or more on radiographic imaging; there were two complete responders, one whom had no radiographic evidence of tumor for 23 months after a single infusion of Tf-CRM107. Eighty-eight percent of patients had demonstrable reduction in tumor volume or a zone of necrosis on follow-up imaging. No treatment-related deaths, life-threatening or any systemic toxicities were noted. The MTD of Tf-CRM107 was 0.67μg/ml delivered in 40 ml; MTD at other volumes could not be determined due to insufficient patient numbers. This trial was followed by a multicenter Phase II trial (78), enrolling patients with a diagnosis of recurrent GBM or AA. The protocol in this study utilized two catheters for infusion of Tf-CRM107 at a concentration of 0.67μg/ml in 40ml, with a delivery rate not to exceed 0.4 ml/hr between the two catheters. Among the 44 patients enrolled in this study, a radiographic reduction of 50% or greater in tumor volume was noted in 35% of patients. This included five patients with a complete response and seven with partial responses. Nine patients had stable disease and the remainder had progressive disease. The median survival was 37 weeks; one patient survived 160 weeks. All the infusions were well tolerated, with one death attributable to the withdrawal of patient care.
In May of 2004, a Phase III trial began for patients diagnosed with unresectable GBM. The trial expects to enroll 323 patients, randomized to Tf-CRM107 or best standard of care in a ratio of 2:1.
Other Agents in Development Using CED: I 131 -labeled Chimeric Monoclonal Antibody (Cotara™):
Monoclonal antibodies represent another powerful method of targeting tumor-specific antigen. With Cotara™, a chimeric monoclonal antibody labeled with I 131 , the investigators targeted the histone H1 complexed to DNA in the necrotic core of malignant solid tumors; this intracellular antigen is specific to necrotic tumor and is found in many solid tumors (79), including gliomas. Early preclinical data indicated that Cotara™ is renally excreted and is not retained by any major visceral organs, including the brain, when administered intravenously. However, in mice bearing tumors in their thighs, there was excellent uptake of Cotara™, which correlated with the degree of central necrosis seen on histologic exami- nation. Ultimately, in mice bearing tumors in their thighs, it was demonstrated that the administration of CotaraTM results in 25% complete tumor regression and an overall 88% tumor regression rate (79). Based on these data, the benefit of Cotara™ was investigated for intracranial use.
In a Phase I/II study, 51 patients with histologically confirmed diagnosis of malignant glioma (37 recurrent GBM, eight newly diagnosed GBM, six recurrent AA) received Co-tara™ by CED through one or two catheters over 24 hours (80). It was determined that between 1.0 and 1.5 mCi/cm 3 of clinical target tumor volume was safe; overall, 79% of patients received 90 to 110% of the prescribed administered activity of Cotara. The infusions were well tolerated with some Grade III and rare Grade IV adverse events, such as hemiparesis, headache, seizure, aphasia, weakness, and pyrexia, reported in 8-10% of the patients. One patient died as a result of symptoms relating to radiation-induced necrotic changes. The spatial distribution of Cotara™ was measured by singlephoton emission computed tomography (SPECT) two weeks after infusion. In the six patients studied, 46 to 88% tumor coverage was seen; longer periods of CED (48 versus 24 hours) infusion did not result in increased coverage. Early efficacy data among the twelve patients receiving between 1.25 and 2.5 mCi/cm 3 demonstrated one partial response, six stable diseases, and four with disease progression. Currently, this agent is being evaluated by the New Approaches to Brain Tumor Therapy consortium where 28 patients with GBM at first or second relapse will be treated.
Paclitaxel: Paclitaxel, a chemotherapeutic agent in clinical use for many cancers, was first derived from the bark of the Pacific yew tree (Taxus brevifolia). Its antineoplastic mechanism of action, the induction of mitotic block at metaphase/ anaphase, stems from the promotion of an altered microtubule assembly that the cell cannot disassemble (81). Use of paclitaxel in the treatment of high grade gliomas has been investigated in the past. Although initial in vitro (82) and in vivo (83) studies demonstrated efficacy, this did not translate to clinical efficacy (84, 85), due to the unfavorable pharmacokinetic profile of paclitaxel and its poor CNS penetrance. Therefore, the use of paclitaxel delivered by CED was investigated.
In a Phase I/II study, fifteen patients with histologically confirmed diagnosis of recurrent malignant glioma (13 GBM and two AA) were given five daily doses of 3.6 to 7.2mg of paclitaxel delivered via CED, each dose over a 24-hour period (86). The convective process was monitored using daily diffusion-weighted MRI imaging (87). Five complete and six partial responses were seen. This high response rate is tempered by a high complication rate, which included six patients with chemical meningitis, three with infections, and four with transient neurological deterioration due to cerebral edema. These authors report the use of a novel delivery tech-nique to re-investigate the application of previously "failed" agent in the treatment of malignant gliomas. Future studies with other similar agents are anticipated.
EGF/Diphtheria Toxin (DAB 389 EGF):
In a concept similar to the development of TP38, EGFR was chosen as the tumor selective target in the development of DAB 389 EGF, which combines the natural ligand to the EGFR, EGF, and the diphtheria toxin.
DAB 389 EGF has potent in vitro activity against EGFR-overexpressing cell lines (88), with efficacy proportional to the density of EGFR expression (89). Confirming the very specific nature of targeted cytotoxins, one glioma cell line not expressing EGFR was found to be not susceptible to the cytotoxic effects of DAB 389 EGF.
In in vivo testing, nude mice bearing U87MG human glioma cells in the flank were treated IT with DAB 389 EGF for three to six doses on alternate days. The MTD was 3μg every other day. At this dose, tumor regression was seen in all animals; however, relapse was seen in 25% of the animals at one month but tumors were responsive to a second treatment with DAB 389 EGF. Testing of this agent against animals bearing intracranial tumor is awaited, and a favorable outcome could pave the way for clinical testing.
CpG Oligodeoxynucleotide : Rather than address a particular tumor-specific antigen, this group (90) is attempting to harness the ability of the immune system to select antigens by taking the strategy of boosting the host's local immunity at the tumor level.
CpG motifs are more frequent in the genomes of virulent organisms such as bacteria and viruses than of vertebrates. It has been shown that these CpG motifs cause immunostimulating activity (91), directing the immune system toward the Th1, or innate, phenotype. For many investigators working with the antisense approach to targeted protein knock-down, it is desirable to minimize the inclusion of these CpG motifs in the design of the oligodeoxynucleotides (ODNs) to separate sequence effect to the more non-specific effect stimulated by these CpG motifs; however, these investigators (92) took the approach of designing an ODN containing CpG motifs to specifically enhance the immune response. CpG-28 is a phosphorothioate ODN administered by CED IT.
In vivo, direct tumor injection of CpG-28 into A/J mice bearing the neuro2a neuroblastoma in their flank resulted in complete tumor regression and long-term immunity (90). Furthermore, in an intracranial syngeneic glioma model using CNS1 tumors, a single intratumoral injection of CpG-28 resulted in long-term survival and tumor eradication in 85% of the animals (93). An interesting in vivo observation was made by Meng et al. (96) in which the survival of Fischer 344 rats bearing 9L glioma was enhanced when CpG-28 was combined with radiotherapy; the addition was hypothesized to result in increased tumor antigen release and enhanced immunostimulation. In immunocompromised mice, a benefit of combined CpG-28 and radiotherapy was not observed (94). In the Fisher 344 rats, the animals surviving long-term were shown to have immunity to further flank tumor challenge by 9L glioma but not to another tumor, RG2. How this finding translates to human trials is unknown but will be of interest (95). A concern of activating the immune system is the potential for autoimmune syndromes; however, in treated animals, neuronal antibodies were not found, their brains were histologically normal and they remained neurologically uncompromised (96).
The results of using CpG-28 in a Phase I trial was recently reported (92) among 24 patients with recurrent GBM. The dose of CpG-28 delivered by CED through one or two catheters was between 0.5 to 20mg and generally well tolerated. Among this cohort, seven patients had grade 3 adverse effects, such as seizure, pyrexia, and lymphopenia, and one patient experienced a dose-limiting toxicity with increase in aphasia and hemiparesis with incomplete recovery. However, no treatment-related deaths were reported. Two minor clinical responses were seen but the overall median survival was 7.2 months. In an immunomodulatory strategy such as this, the role of maintenance corticosteroids and its effect on clinical response needs to be evaluated. Antisense ODN (AP 12009) : Many malignancies, including high grade gliomas, have increased expression of TGF-β2, which has been shown to play a role in neoplastic cell proliferation, angiogenesis, and local immunosuppression (97), while it is not expressed in normal brain (98). Investigators approached targeting TGF-β2 by utilizing the sequence specificity of short (18-mer) oligodeoxynucleotides with phosphorothioate modification (97). In twelve glioma cell lines, their cell proliferation was inhibited by the in vitro administration of TGF-β2 phosphorothioate ODN compared to control and this was further validated using Northern blot analysis and enzyme-linked immunosorbent assay (ELISA) (99); up to 73% decrease in TGF-β2 expression was achieved (100). In addition, administration of the TGF-β2 phosphorothioate ODN to glioma cell lines in vitro has also been shown to reverse the immunosuppression in autologous peripheral blood mononuclear cells (101). Further preclinical studies, including a seven-day CED delivery to normal rabbit brain, confirmed the safety and toleratibility of AP 12009 in several animals (97).
TGF-β2 Specific
Three Phase I/II dose escalation studies were performed beginning in 2000, enrolling a total of 24 patients with a diagnosis of recurrent or progressive grade III/IV tumors to deter-mine the MTD. These patients were treated with up to twelve cycles of AP 12009 by CED. Of note, the third study utilized an implanted pump system that allowed repeated treatments as an outpatient basis. The CED was well tolerated with one unspecified "serious" adverse event reported; the MTD was not determined in these trials. Median overall survival among five patients with AA was 146.6 weeks and 44.0 weeks for the 19 patients with GBM; one patient with AA had a complete response after only one cycle of AP 12009, surviving 195 weeks. AP 12009 is now undergoing a Phase II study among patients with recurrent high grade gliomas, comparing to standard chemotherapy of temozolomide or PCV in those patients who had received temozolomide before study entry (102).
Conclusion
Despite a multidisciplinary approach utilizing surgery, radiation therapy, and chemotherapy, the prognosis for patients with malignant gliomas remains poor. The infiltrative nature of gliomas, requires adjuvant therapies to address this regional phenomenon outside the contrast-enhancing zone on imaging. Due to physiological limitations and barriers, many promising therapeutic agents, including large molecules such as targeted toxins have been ineffective. The application of local and convection-enhanced delivery may change our ability to treat more regionally. Rather than rely on the ability systemically administered agents to reach the brain, CED allowed the direct infusion of agents at high concentrations, while avoiding systemic side effects. Furthermore, this strategy allows delivery of essentially any agent to the brain, regardless of molecular weight or charge, although small lipophilic agents, which readily cross the blood-brain barrier, are not suitable candidates. Limitations of CED will be in the form of local toxicities.
The advance in knowledge about the biology of high grade gliomas and cancer in general outpaced our ability to deliver agents designed to target tumor-specific markers. Rather than rely on screening a broad array of natural and synthetic compounds for a biological activity of interest, the exponentially expanding data on glioma-specific molecular events allowed investigators to design agents with tremendous specificity and toxicity for diseased cells. Combined with local and CED, these targeted therapeutics finally had the chance to prove their clinical utility. As a result, many rationally designed agents are entering or are in advanced stages of clinical testing.
Many of the glioma-specific targets described in this review are not uniformly found in high grade gliomas; these tumors contain a heterogeneous population of neoplastic cells, each with a different molecular and phenotypic signature (103). If so, it would be of importance to test the potential additive or synergistic effects of combination therapies, which was reported recently by Liu et al. (104) . In their report, combination therapy of DAB 389 EGF, a fusion protein between epidermal growth factor and diphtheria toxin (105), and IL13-PE38QQR demonstrated greater cytotoxic effect on cell lines than either agent alone or in an additive fashion; indeed, synergistic activity was found.
Although the utility of CED in Neuro-Oncology has been demonstrated, there are many areas for improvement and refinement. For example, in the preclinical and clinical phases of Tf-CRM107 development, the investigators noted that many imaging studies demonstrated evidence of small vessel thrombosis and petechial hemorrhage, likely a consequence of Tf-CRM107 on the capillary endothelial cells that are known to express TfR (55). To combat this side effect, the investigators utilized IV chloroquine, which has poor BBB permeability and is known to block the cytotoxicity of Diphtheria toxin, to reduce the agent's effect on the vasculature while maintaining the antitumor efficacy. In doing so, the investigators found, in vivo, that the MTD of Tf-CRM107 was increased, suggesting that the simultaneous IV administration of chloroquine may increase the therapeutic window of Tf-CRM107 (106).
Other mechanistic issues also require further study. It was noted that among patients who participated in the IL13-PE38QQR trials, those who had two or more "optimally" placed catheters had a greater overall survival. What constitutes an "optimal" catheter placement warrants further investigation, as does the timing of catheter placement, the optimal type of catheter, number of doses, et cetera. In addition, delivery of agents by CED is a time-consuming process with the potential for infectious complications. Depending on the pharmacokinetic profile of the targeted therapeutic, it may also be hypothesized that longer infusions will yield greater clinical effects; if so, the possibility of implanted pumps should be considered, which has been shown to be feasible in macaque monkeys (107).
It is hoped that continued advances in our understanding of the biology of malignant gliomas, in combination with refinements in the delivery and targeting of agents to gliomas, will translate to an increase in survival and an improvement in the quality of life among these patients.
